CN1720243A - 具有同时阻滞l－型钙通道和抑制3型磷酸二酯酶活性能力的二氢吡啶化合物 - Google Patents

具有同时阻滞l－型钙通道和抑制3型磷酸二酯酶活性能力的二氢吡啶化合物 Download PDF

Info

Publication number
CN1720243A
CN1720243A CNA2003801052200A CN200380105220A CN1720243A CN 1720243 A CN1720243 A CN 1720243A CN A2003801052200 A CNA2003801052200 A CN A2003801052200A CN 200380105220 A CN200380105220 A CN 200380105220A CN 1720243 A CN1720243 A CN 1720243A
Authority
CN
China
Prior art keywords
group
alkyl
alkenyl
alkynyl
optional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801052200A
Other languages
English (en)
Chinese (zh)
Inventor
G·S·哈米敦
H·J·莱敦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WAKAL THERAPEUTICS Inc
Original Assignee
WAKAL THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WAKAL THERAPEUTICS Inc filed Critical WAKAL THERAPEUTICS Inc
Publication of CN1720243A publication Critical patent/CN1720243A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2003801052200A 2002-10-07 2003-10-07 具有同时阻滞l－型钙通道和抑制3型磷酸二酯酶活性能力的二氢吡啶化合物 Pending CN1720243A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41625402P 2002-10-07 2002-10-07
US60/416,254 2002-10-07

Publications (1)

Publication Number Publication Date
CN1720243A true CN1720243A (zh) 2006-01-11

Family

ID=32093831

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801052200A Pending CN1720243A (zh) 2002-10-07 2003-10-07 具有同时阻滞l－型钙通道和抑制3型磷酸二酯酶活性能力的二氢吡啶化合物

Country Status (14)

Country Link
US (1) US7098211B2 (enExample)
EP (1) EP1554267A1 (enExample)
JP (1) JP2006504738A (enExample)
KR (1) KR20050070036A (enExample)
CN (1) CN1720243A (enExample)
AU (1) AU2003275450A1 (enExample)
BR (1) BR0315103A (enExample)
CA (1) CA2501534A1 (enExample)
MX (1) MXPA05003640A (enExample)
NO (1) NO20052169L (enExample)
PL (1) PL376405A1 (enExample)
RU (1) RU2005110062A (enExample)
WO (1) WO2004033444A1 (enExample)
ZA (1) ZA200502711B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009092301A1 (zh) * 2008-01-21 2009-07-30 Cosunter Pharmaceuticl Company 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途
CN102223882A (zh) * 2008-11-25 2011-10-19 贝林格尔.英格海姆维特梅迪卡有限公司 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
CN115838351A (zh) * 2022-12-06 2023-03-24 昆明理工大学 4-烷基-1,4-二氢吡啶化合物及其制备方法和应用
CN116693454A (zh) * 2023-06-06 2023-09-05 中山大学 一种取代氰基喹啉酮类化合物及其制备方法与应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094806B2 (en) * 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
WO2005016885A2 (en) * 2003-08-14 2005-02-24 Artesian Therapeutics, Inc. COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE
WO2005035505A2 (en) * 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20090298872A1 (en) * 2004-12-13 2009-12-03 Irm Llc Compounds and compositions as modulators of steroidal receptors and calcium channel activities
NL1028564C2 (nl) * 2005-03-17 2006-09-20 Rademaker Holding B V Toepassing van een coumarine-groep omvattende derivaten voor de bereiding van een antiviraal middel, coumarine-group omvattende derivaten, een werkwijze voor de bereiding daarvan, en farmaceutische preparaten die deze bevatten.
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2009149837A1 (en) 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
GB201017783D0 (en) * 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57200386A (en) 1981-06-04 1982-12-08 Yoshitomi Pharmaceut Ind Ltd Novel 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its salts
CH655110A5 (de) * 1982-09-03 1986-03-27 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten.
PL140069B1 (en) 1982-12-21 1987-03-31 Pfizer Method of obtaining new derivatives of dihydropiridine
GB8306666D0 (en) 1983-03-10 1983-04-13 Pfizer Ltd Therapeutic agents
US4568677A (en) 1983-07-23 1986-02-04 Pfizer Inc. 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents
DE3445852A1 (de) 1984-12-15 1986-06-19 Bayer Ag, 5090 Leverkusen Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB8501395D0 (en) 1985-01-19 1985-02-20 Pfizer Ltd Dihydropyridine anti-ischaemic & anti-hypertensive agents
US4820842A (en) 1986-11-19 1989-04-11 Warner-Lambert Company 2-substituted-1,4-dihydropyridines
US4723014A (en) 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3712369A1 (de) 1987-04-11 1988-10-27 Bayer Ag Substituierte 5-nitro-1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung
DE3712371A1 (de) 1987-04-11 1988-10-27 Bayer Ag Substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung
DE3716652A1 (de) 1987-05-19 1988-12-08 Bayer Ag Dioxyalkylenaryl-dihydropyridine, zwischenprodukte zu ihrer herstellung, verfahren zu ihrer herstellung und ihre verwendung
DE3724909A1 (de) 1987-07-28 1989-02-09 Bayer Ag Neue substituierte nitro-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung
US5096904A (en) 1989-09-01 1992-03-17 Glaxo Inc. Pyridazinones having cardiotonic and beta blocking activities
WO1992006087A1 (en) 1990-10-02 1992-04-16 Kaken Pharmaceutical Co., Ltd. Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient
US5100892A (en) 1990-11-13 1992-03-31 Glaxo Inc. Dihydropyridine vasodilator agents
US5258519A (en) 1990-11-13 1993-11-02 Glaxo Inc. Dihydropyridine vasodilators agents
MXPA03000436A (es) 2000-07-18 2003-06-24 Yamanouchi Pharma Co Ltd Medicamentos que compreden derivados de dicianopiridina.
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009092301A1 (zh) * 2008-01-21 2009-07-30 Cosunter Pharmaceuticl Company 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途
CN102223882A (zh) * 2008-11-25 2011-10-19 贝林格尔.英格海姆维特梅迪卡有限公司 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
CN102223882B (zh) * 2008-11-25 2016-02-03 贝林格尔.英格海姆维特梅迪卡有限公司 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
CN115838351A (zh) * 2022-12-06 2023-03-24 昆明理工大学 4-烷基-1,4-二氢吡啶化合物及其制备方法和应用
CN116693454A (zh) * 2023-06-06 2023-09-05 中山大学 一种取代氰基喹啉酮类化合物及其制备方法与应用

Also Published As

Publication number Publication date
AU2003275450A1 (en) 2004-05-04
PL376405A1 (en) 2005-12-27
ZA200502711B (en) 2006-07-26
JP2006504738A (ja) 2006-02-09
EP1554267A1 (en) 2005-07-20
WO2004033444A1 (en) 2004-04-22
US20040242648A1 (en) 2004-12-02
RU2005110062A (ru) 2006-01-10
NO20052169L (no) 2005-06-08
MXPA05003640A (es) 2005-11-17
US7098211B2 (en) 2006-08-29
BR0315103A (pt) 2005-08-16
CA2501534A1 (en) 2004-04-22
KR20050070036A (ko) 2005-07-05

Similar Documents

Publication Publication Date Title
JP6113285B2 (ja) Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン
JP6262732B2 (ja) Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7098211B2 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
KR20130142137A (ko) 모노아실글리세롤 리파아제 억제제로서의 피페리딘-4-일-아제티딘 다이아미드
CN1265098A (zh) 抑制因子xa的杂环衍生物
CN103550218A (zh) 用于调节gpr119 g蛋白偶联受体的方法及所选化合物
KR20160030403A (ko) 치료학적 활성 화합물 및 이들의 사용 방법
CN1976906A (zh) 用作parp抑制剂的取代2－烷基喹唑啉酮衍生物
KR20140015131A (ko) 칸나비노이드 수용체 조절제
CN1344257A (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
FR2644786A1 (fr) Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
CN1064272A (zh) 吡喃基氰基胍衍生物
JP2017100950A (ja) オキソ複素環誘導体
KR20140083058A (ko) G 단백질-커플링된 Mas 수용체의 조절제 및 그와 관련된 장애의 치료
JP7106623B2 (ja) 核内受容体に対して活性の化合物
WO2013005755A1 (ja) メチルピペリジン誘導体
WO2015006591A1 (en) 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
CN1062289A (zh) 治疗心、血管肥大及增生的方法
CN1071754C (zh) 嘧啶基吡唑衍生物
CN1134695A (zh) 具有血小板凝聚抑制作用的新颖化合物
TW200811137A (en) mGluR5 modulators II
CN1033805A (zh) 哌啶基化合物
CN1014245B (zh) 制备新的吡唑啉衍生物的方法
CN86104681A (zh) 治疗老年精神病的环酰胺和酰亚胺的二氮杂苯基哌啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication